We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-19, within 24 hours after starting organ support in the intensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback